Announcements Trials
Browse Landscape

Phase

Phase NA 26Phase 3 14Phase 2 10Phase 1 8Phase 1/2 5Phase 4 4Phase 2/3 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 85Glioblastoma 82Pancreatic Neoplasms 75Glioma 65Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 54Colorectal Neoplasms 54Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 50Squamous Cell Carcinoma of Head and Neck 46Recurrence 46Ovarian Neoplasms 45Lymphoma 39Lymphoma, Non-Hodgkin 37Lymphoma, B-Cell 36Sarcoma 35Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 33Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Breast Diseases × Clear all
NCT04341129 2023-12-05

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

University of Chicago

Phase EARLY_PHASE1 Completed
50 enrolled
Breast

Breast Diseases, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Fibroadenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡